Search research articles
Contact Us
Filters
Showing results (211-220 of 253) with videos related to
Page
of 26
Sort By:
Leukemia & Lymphoma
|
January 21, 2017
A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma
Beata Holkova, Victor Yazbeck, Maciej Kmieciak, et al.
Plant Science : an International Journal of Experimental Plant Biology
|
May 8, 2026
The cytokinin oxidase/dehydrogenase MdCKX4 regulates drought tolerance in Malus domestica
Tong Li, Yu-Feng Zhang, Joy Xin-Yue Zhai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 31, 2025
Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/<i>TP53</i> Mutation: SEQUOIA Arm D Results
Mazyar Shadman, Talha Munir, Shuo Ma, et al.
Blood
|
June 11, 2021
Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy
Shuo Ma, John F Seymour, Danielle M Brander, et al.
Science Advances
|
September 3, 2025
Hybrid pneumatic-hydraulic actuation for MRI-guided robotic stereotactic neurointervention
Shaoping Huang, Zhao He, Yi Chen, et al.
Blood Advances
|
July 24, 2025
Nivolumab in Combination with R-CHOP for Treatment-Naïve Diffuse Large B-Cell Lymphoma: An Evaluation of Safety and Efficacy
Oluwatobi Odetola, Shuo Ma, Jane N Winter, et al.
Blood Cancer Journal
|
February 19, 2021
Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication
Pin Lu, Shengchun Wang, Carrie A Franzen, et al.
Leukemia & Lymphoma
|
June 21, 2023
Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma
Danielle S Wallace, Chris Rowland, Brian T Hill, et al.
Blood
|
April 27, 2019
Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables
Andrew W Roberts, Shuo Ma, Thomas J Kipps, et al.
Blood Advances
|
November 23, 2020
Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis
Ariela Noy, Sven de Vos, Morton Coleman, et al.
Page
of 26
Search research articles
Search
Showing results (211-220 of 253) with videos related to
Sort By:
Page
of 26
Leukemia & Lymphoma
|
January 21, 2017
A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma
Beata Holkova, Victor Yazbeck, Maciej Kmieciak, et al.
Plant Science : an International Journal of Experimental Plant Biology
|
May 8, 2026
The cytokinin oxidase/dehydrogenase MdCKX4 regulates drought tolerance in Malus domestica
Tong Li, Yu-Feng Zhang, Joy Xin-Yue Zhai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 31, 2025
Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/<i>TP53</i> Mutation: SEQUOIA Arm D Results
Mazyar Shadman, Talha Munir, Shuo Ma, et al.
Blood
|
June 11, 2021
Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy
Shuo Ma, John F Seymour, Danielle M Brander, et al.
Science Advances
|
September 3, 2025
Hybrid pneumatic-hydraulic actuation for MRI-guided robotic stereotactic neurointervention
Shaoping Huang, Zhao He, Yi Chen, et al.
Blood Advances
|
July 24, 2025
Nivolumab in Combination with R-CHOP for Treatment-Naïve Diffuse Large B-Cell Lymphoma: An Evaluation of Safety and Efficacy
Oluwatobi Odetola, Shuo Ma, Jane N Winter, et al.
Blood Cancer Journal
|
February 19, 2021
Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication
Pin Lu, Shengchun Wang, Carrie A Franzen, et al.
Leukemia & Lymphoma
|
June 21, 2023
Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma
Danielle S Wallace, Chris Rowland, Brian T Hill, et al.
Blood
|
April 27, 2019
Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables
Andrew W Roberts, Shuo Ma, Thomas J Kipps, et al.
Blood Advances
|
November 23, 2020
Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis
Ariela Noy, Sven de Vos, Morton Coleman, et al.
Page
of 26